Literature DB >> 1372785

Pharmacology of bepridil.

A Gill1, S F Flaim, B P Damiano, S P Sit, M D Brannan.   

Abstract

Bepridil is an antianginal agent with multiple therapeutic actions. It decreases calcium influx through potential-dependent and receptor-operated sarcolemmic calcium channels and acts intracellularly as a calmodulin antagonist and calcium sensitizer. Thus, in cardiac muscle it enhances the sensitivity of troponin C to calcium, stimulates myofibrillar adenosine triphosphatase activity, removes calmodulin's inhibitory effect on sarcoplasmic reticulum calcium release, and inhibits sodium-calcium exchange--actions that tend to offset the effects of calcium influx blockade on cardiac contractile force. However, in vascular smooth muscle where the calcium-calmodulin complex promotes muscle contraction by activating myosin light-chain kinase phosphorylation of contractile proteins, calmodulin antagonism, coupled with bepridil's blockade of calcium influx, leads to vasorelaxation. In animal models of ischemia, bepridil and other calmodulin inhibitors show antiarrhythmic efficacy following reperfusion. Additionally, interfering with calmodulin's role in sympathetic nerve terminal function may help to limit the ischemia-induced catecholamine release that contributes to arrhythmogenesis. Bepridil shows a lidocaine-like fast kinetic block of inward sodium current (as distinct from the slow or intermediate kinetic inhibition expressed by encainide or quinidine, respectively). This inhibition is pH-dependent; activity is expressed to a greater degree at lower pH levels. This, this potentially antiarrhythmic mechanism is activated by conditions of ischemia. Bepridil's blockade of outward potassium currents and its inhibition of sodium-calcium exchange increase action potential duration and ventricular refractoriness, prolong the QT interval, and form the basis for a class III antiarrhythmic mechanism. Because hypokalemia also prolongs the QT interval, the addition of bepridil in the presence of hypokalemia can lead to excessive prolongation. Bepridil both increases myocardial oxygen supply through coronary vasodilation and decreases myocardial oxygen demand through mild heart rate and afterload reduction, and shows potential antiarrhythmic activity through class IB, III, and IV mechanisms.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1372785     DOI: 10.1016/0002-9149(92)90953-v

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

1.  Alteration of the [Ca(2+)](i)-force relationship during the vasorelaxation induced by a Ca(2+) channel blocker SR33805 in the porcine coronary artery.

Authors:  S Ieiri; K Hirano; J Nishimura; S Suita; H Kanaide
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

2.  Zebrafish as a model for cardiovascular development and disease.

Authors:  Catherine T Nguyen; Qing Lu; Yibin Wang; Jau-Nian Chen
Journal:  Drug Discov Today Dis Models       Date:  2008

3.  Bepridil differentially inhibits two delayed rectifier K(+) currents, I(Kr) and I(Ks), in guinea-pig ventricular myocytes.

Authors:  J C Wang; T Kiyosue; K Kiriyama; M Arita
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

4.  Drug-Induced QT Prolongation and Torsade de Pointes in Spontaneous Adverse Event Reporting: A Retrospective Analysis Using the Japanese Adverse Drug Event Report Database (2004-2021).

Authors:  Mayu Uchikawa; Masayuki Hashiguchi; Tsuyoshi Shiga
Journal:  Drugs Real World Outcomes       Date:  2022-08-22

Review 5.  Bepridil. A review of its pharmacological properties and therapeutic use in stable angina pectoris.

Authors:  L M Hollingshead; D Faulds; A Fitton
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

6.  MicroRNA-27a controls the intracellular survival of Mycobacterium tuberculosis by regulating calcium-associated autophagy.

Authors:  Feng Liu; Jianxia Chen; Peng Wang; Haohao Li; Yilong Zhou; Haipeng Liu; Zhonghua Liu; Ruijuan Zheng; Lin Wang; Hua Yang; Zhenling Cui; Fei Wang; Xiaochen Huang; Jie Wang; Wei Sha; Heping Xiao; Baoxue Ge
Journal:  Nat Commun       Date:  2018-10-16       Impact factor: 14.919

7.  Post-surgical adhesions are triggered by calcium-dependent membrane bridges between mesothelial surfaces.

Authors:  Adrian Fischer; Tim Koopmans; Pushkar Ramesh; Simon Christ; Maximilian Strunz; Juliane Wannemacher; Michaela Aichler; Annette Feuchtinger; Axel Walch; Meshal Ansari; Fabian J Theis; Kenji Schorpp; Kamyar Hadian; Philipp-Alexander Neumann; Herbert B Schiller; Yuval Rinkevich
Journal:  Nat Commun       Date:  2020-06-17       Impact factor: 14.919

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.